Literature DB >> 17498992

Murine model (Galns(tm(C76S)slu)) of MPS IVA with missense mutation at the active site cysteine conserved among sulfatase proteins.

Shunji Tomatsu1, Carole Vogler, Adriana M Montaño, Monica Gutierrez, Hirotaka Oikawa, Vu Chi Dung, Tadao Orii, Akihiko Noguchi, William S Sly.   

Abstract

Mucopolysaccharidosis IVA (MPS IVA) is an autosomal recessive disorder caused by deficiency of N-acetylgalactosamine-6-sulfate sulfatase (GALNS), required for degradation of keratan sulfate and chondroitin-6-sulfate. In order to study the effects of a missense mutation in the active site cysteine in the GALNS gene that is conserved in all mammalian sulfatases, we produced a p.C76S (an active site replacement) knock-in mouse by replacing the Cys76 with Ser in the endogenous murine Galns by targeted mutagenesis. Homozygous Galns(tm(C76S)slu) mice had no detectable GALNS enzyme activity. At age of 2-4 months, lysosomal storage was present primarily within reticuloendothelial cells such as Kupffer cells and spleen sinusoidal lining cells. Vacuolar change was present in glomerular visceral epithelial cells and was not present in hepatocytes or renal tubular cells. In the brain, hippocampal and neocortical neurons and meningeal cells showed lysosomal storage. Radiographs revealed no change in the skeletal bones of mice up to 12 months old. Thus, the Galns(tm(C76S)slu) mice had visceral storage of GAGs in organs but lacked the skeletal features of human MPS IVA. In contrast to a previously reported transgenic model (Galns(tm(hC79S.mC76S)slu)), in which the inactive human GALNS transgene was overexpressed, no reduction in other sulfatases was observed. In addition, the Galns(tm(C76S)slu) mice displayed milder storage. We conclude that the milder phenotype is characteristic of isolated GALNS deficiency while the more severe phenotype reflected in the Galns(tm(hC79S.mC76S)slu) mice was due to deficiency of other sulfatases caused by oversaturation of the sulfate modifying enzyme by the inactive human gene product.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17498992     DOI: 10.1016/j.ymgme.2007.02.009

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  16 in total

1.  Mechanism of shortened bones in mucopolysaccharidosis VII.

Authors:  Jason A Metcalf; Yanming Zhang; Matthew J Hilton; Fanxin Long; Katherine P Ponder
Journal:  Mol Genet Metab       Date:  2009-03-25       Impact factor: 4.797

2.  Expression in CHO cells and pharmacokinetics and brain uptake in the Rhesus monkey of an IgG-iduronate-2-sulfatase fusion protein.

Authors:  Jeff Zhiqiang Lu; Ruben J Boado; Eric K-W Hui; Qing-Hui Zhou; William M Pardridge
Journal:  Biotechnol Bioeng       Date:  2011-03-15       Impact factor: 4.530

Review 3.  Mucopolysaccharidosis IVA and glycosaminoglycans.

Authors:  Shaukat Khan; Carlos J Alméciga-Díaz; Kazuki Sawamoto; William G Mackenzie; Mary C Theroux; Christian Pizarro; Robert W Mason; Tadao Orii; Shunji Tomatsu
Journal:  Mol Genet Metab       Date:  2016-11-29       Impact factor: 4.797

4.  Enzyme replacement therapy in newborn mucopolysaccharidosis IVA mice: early treatment rescues bone lesions?

Authors:  Shunji Tomatsu; Adriana M Montaño; Hirotaka Oikawa; Vu Chi Dung; Amiko Hashimoto; Toshihiro Oguma; Monica L Gutiérrez; Tatsuo Takahashi; Tsutomu Shimada; Tadao Orii; William S Sly
Journal:  Mol Genet Metab       Date:  2014-06-04       Impact factor: 4.797

5.  Activity of daily living for Morquio A syndrome.

Authors:  Eriko Yasuda; Yasuyuki Suzuki; Tsutomu Shimada; Kazuki Sawamoto; William G Mackenzie; Mary C Theroux; Christian Pizarro; Li Xie; Freeman Miller; Tariq Rahman; Heidi H Kecskemethy; Kyoko Nagao; Thierry Morlet; Thomas H Shaffer; Yasutsugu Chinen; Hiromasa Yabe; Akemi Tanaka; Haruo Shintaku; Kenji E Orii; Koji O Orii; Robert W Mason; Adriana M Montaño; Toshiyuki Fukao; Tadao Orii; Shunji Tomatsu
Journal:  Mol Genet Metab       Date:  2016-04-25       Impact factor: 4.797

Review 6.  Morquio A syndrome: diagnosis and current and future therapies.

Authors:  Shunji Tomatsu; Eriko Yasuda; Pravin Patel; Kristen Ruhnke; Tsutomu Shimada; William G Mackenzie; Robert Mason; Mihir M Thacker; Mary Theroux; Adriana M Montaño; Carlos J Alméciga-Díaz; Luis A Barrera; Yasutsugu Chinen; William S Sly; Daniel Rowan; Yasuyuki Suzuki; Tado Orii
Journal:  Pediatr Endocrinol Rev       Date:  2014-09

7.  Assessment of bone dysplasia by micro-CT and glycosaminoglycan levels in mouse models for mucopolysaccharidosis type I, IIIA, IVA, and VII.

Authors:  Daniel J Rowan; Shunji Tomatsu; Jeffrey H Grubb; Adriana M Montaño; William S Sly
Journal:  J Inherit Metab Dis       Date:  2012-09-13       Impact factor: 4.982

8.  Radiographic evaluation of bones and joints in mucopolysaccharidosis I and VII dogs after neonatal gene therapy.

Authors:  Ramin Sedaghat Herati; Van W Knox; Patricia O'Donnell; Marina D'Angelo; Mark E Haskins; Katherine P Ponder
Journal:  Mol Genet Metab       Date:  2008-08-15       Impact factor: 4.797

9.  Current and emerging treatments and surgical interventions for Morquio A syndrome: a review.

Authors:  Shunji Tomatsu; William G Mackenzie; Mary C Theroux; Robert W Mason; Mihir M Thacker; Thomas H Shaffer; Adriana M Montaño; Daniel Rowan; William Sly; Carlos J Alméciga-Díaz; Luis A Barrera; Yasutsugu Chinen; Eriko Yasuda; Kristen Ruhnke; Yasuyuki Suzuki; Tadao Orii
Journal:  Res Rep Endocr Disord       Date:  2012-12

10.  Current therapies for Morquio A syndrome and their clinical outcomes.

Authors:  Kazuki Sawamoto; Yasuyuki Suzuki; William G Mackenzie; Mary C Theroux; Christian Pizarro; Hiromasa Yabe; Kenji E Orii; Robert W Mason; Tadao Orii; Shunji Tomatsu
Journal:  Expert Opin Orphan Drugs       Date:  2016-07-28       Impact factor: 0.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.